The primary roadblock that has limited the basic and translational investigation of many hematologic malignancies is the paucity of in vitro and in vivo models.
The most basic questions relevant to pathogenesis and targeting of these diseases have remained unanswered due to the lack of tractable cell lines and patient-derived xenografts (PDXs).
Our laboratory leads a multi-institutional effort across Dana-Farber, the Brigham and Women's Hospital, and Boston Children's Hospital to generate models of myeloid and lymphoid tumors. Our ongoing efforts have generated >250 leukemias and >50 lymphomas that passage through immunocompromised animals. We provide anyone within the academic and commercial community access to these models and all of the associated de-identified data (see www.PRoXe.org).